Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Amneal Pharmaceuticals (AMRX) insider selling reported on Form 4. Executive Vice President & CFO Tasos Konidaris disposed of a total of 499,730 shares across three sale dates: 161,365 shares on 08/13/2025 at a weighted average price of $9.22, 119,206 shares on 08/14/2025 at $9.30, and 219,159 shares on 08/15/2025 at $9.43. After these transactions the reporting person beneficially owned 122,152 shares.
The filing shows the sales were executed in multiple transactions with price ranges disclosed in footnotes and signed by an attorney-in-fact. No derivative transactions, grants, or acquisitions are reported on this form and no explanatory statements beyond weighted-average price ranges were provided.
Insider sale notice for Amneal Pharmaceuticals (AMRX). The Form 144 reports a proposed sale of 219,159 common shares with an aggregate market value of $2,057,903.01 to be sold on or about 08/15/2025 on NASDAQ. The filing shows the securities were acquired through RSU vesting on three dates in March 2024 totaling 219,159 shares. The document also discloses recent completed sales by Anastasios Konidaris: 161,635 shares sold on 08/13/2025 for gross proceeds of $1,489,993.93 and 119,206 shares sold on 08/14/2025 for gross proceeds of $1,108,993.36. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Amneal Pharmaceuticals (AMRX) Form 144: This notice reports a proposed sale of 71,694 Class A shares (aggregate market value $663,065) to be sold on or about 08/14/2025 on NASDAQ. The shares were acquired through equity compensation from Amneal Pharmaceuticals on 02/27/2024 (16,950 shares), 03/01/2024 (13,776 shares) and 03/03/2024 (40,968 shares), matching the 71,694 units listed. The filing lists the total Class A shares outstanding as 314,079,309. The notice also discloses sales by the same person in the past three months: 50,000 shares sold on 08/12/2025 for $453,000 and 49,140 shares sold on 05/16/2025 for $370,542. By signing, the seller represents they possess no undisclosed material information about the issuer.
Amneal Pharmaceuticals, Inc. (AMRX) Form 4 shows that reporting person Shah Nikita, listed as Executive Vice President and filing as an officer, sold 50,000 shares of Class A common stock on 08/12/2025. The filing reports a weighted average price of $9.04 and discloses the sales occurred in multiple transactions at prices ranging from $9.03 to $9.07. The sale is reported as a direct disposition.
The filing states the reporting person now beneficially owns 338,929 shares directly. The Form 4 was signed by attorney-in-fact Denis Butkovic on 08/13/2025. No derivative securities are reported on this Form 4.
Amneal Pharmaceuticals insider sale: Jason B. Daly, EVP and Chief Legal Officer, sold 22,000 shares of Class A common stock at a weighted average price of $9.05 per share on 08/12/2025. After the reported sale, Daly directly holds 10,606 shares. The filing notes the sale was executed in multiple transactions with prices ranging from $9.01 to $9.13 and that full per-trade details will be provided to the company or the SEC on request. The Form 4 was submitted by an attorney-in-fact on behalf of the reporting person.
Andrew S. Boyer, Executive Vice President of Amneal Pharmaceuticals (AMRX), reported the sale of Class A common stock on 08/12/2025. The filing shows 33,436 shares were disposed in one or more transactions at a weighted average price of approximately $9.05 per share, with individual trade prices ranging from $9.05 to $9.07.
After these transactions, Boyer directly beneficially owns 256,670 shares. The Form 4 discloses no derivative transactions and includes a footnote stating the sales were executed in multiple transactions and that the reporting person will provide detailed per-price allocation upon request.
Amneal Pharmaceuticals (AMRX) filed a Form 144 disclosing a proposed sale of 169,206 common shares, with an aggregate market value of $1,568,539.00, to occur approximately on 08/13/2025 on NASDAQ through Charles Schwab Corp. The filing shows the shares were acquired by RSU vesting in March 2023 in three tranches: 87,719 on 03/12/2023, 36,197 on 03/01/2023 and 45,290 on 03/03/2023. The notice also records a sale during the past three months: Anastasios Konidaris sold 111,635 shares on 08/13/2025 for gross proceeds of $1,021,157.97. The signee represents there is no undisclosed material adverse information.
Amneal Pharmaceuticals (AMRX) submitted a Rule 144 notice reporting a proposed sale of 111,635 common shares with an aggregate market value of $1,006,947.00. The sale is planned on NASDAQ through Charles Schwab (3000 Schwab Way, Westlake, TX) with an approximate sale date of 08/13/2025. The filing shows 314,079,309 shares outstanding for the issuer.
The shares to be sold were acquired via RSU vesting on 03/01/2022 (23,916 shares) and 03/12/2022 (87,719 shares). The filer reports no securities sold in the past three months. The notice includes the standard representation that the filer does not possess undisclosed material adverse information and references trading-plan/Rule 10b5-1 considerations.
Amneal Pharmaceuticals (AMRX) Form 144 discloses a proposed sale of 33,436 Common Class A shares through Charles Schwab (3000 Schwab Way, Westlake, TX) with an aggregate market value of $304,100.00. The filing reports 314,079,309 shares outstanding and lists the approximate sale date as 08/12/2025 on NASDAQ. The shares were acquired as restricted stock awards from the issuer on 03/03/2025 (14,779 shares) and 03/04/2025 (18,657 shares) and were paid via Equity Compensation. The filer reports Nothing to Report for securities sold in the past three months and includes the standard representation that no material nonpublic information is known.
Amneal Pharmaceuticals (AMRX) Form 144 reports a proposed sale of 22,000 Class A shares through Merrill Lynch with an approximate sale date of 08/12/2025 and an aggregate market value of $198,000. The filing shows the shares were acquired on 03/03/2025 as equity compensation from Amneal Pharmaceuticals and that payment was made on the same date.
The filing lists 18,067,134 shares outstanding and indicates there were no securities sold by the person in the past three months. The filer also represents that they have no undisclosed material adverse information about the issuer.